Treatment Registry
TR-0262 ActiveRecorded September 2026

Compounded semaglutide

Sold by Maves · every compounded semaglutide record

The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.

Recorded initial charges

First month

at least $189

first month, including required fees on record. The published monthly rate excludes one-time and annual fees; introductory and conditional rates may change. Some fee details are unverified or unpublished; this sum does not establish the full amount payable.

Medication · Ongoing, after first month · recorded initial monthly payment$189
Required membership · Amount not published. Maves runs a membership rather than a per-order sale: "The Program is a membership-based service through which eligible Members can obtain limited medical care", and "The Program includes: 12 months of Membership, up to eight discrete medical consults per year." ⛔ The amount is published nowhere in the terms, so none is recorded here. The terms also warn that a visit is billable even if you do not qualify: "even if you do not meet the clinical criteria for participation in the Program, you are responsible for payment of the cost of the Diagnosis Online Visit."Not included

A required charge cannot be included because its amount or billing period is unresolved. This is a partial sum, not the full bill.

Price

TermPer monthCharged today
Ongoing, after first month

“$89 first month then $189/mo after”

Per month$189Charged today$189
Price sources
Visit Maves

We earn nothing from this link. It opens Maves's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PharmacyRed Rock Pharmacy
CancellationYou may cancel your Membership at any time by calling us at +1-307-317-6388, emailing us at [email protected] , or logging into your Secure User account.
MembershipRequired. Amount not published. Maves runs a membership rather than a per-order sale: "The Program is a membership-based service through which eligible Members can obtain limited medical care", and "The Program includes: 12 months of Membership, up to eight discrete medical consults per year." ⛔ The amount is published nowhere in the terms, so none is recorded here. The terms also warn that a visit is billable even if you do not qualify: "even if you do not meet the clinical criteria for participation in the Program, you are responsible for payment of the cost of the Diagnosis Online Visit."

Not yet checked: states, prescriber and consult fee.

Recorded from maveshealth.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — The homepage banner and treatment card advertise 'GLP-1 treatments starting at $99 first month' / 'Starting at $89/month', but neither figure matches the two individual product pages exactly: semaglutide's actual first month is $89 (matches the card, not the $99 banner) and tirzepatide's first month is $184 (matches neither homepage figure). Fetches on this domain returned unusually large raw HTML (page embeds large base64 image data inline), so grep-filtered fetches were used throughout rather than full dumps.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0262
Medication category
compounded semaglutide
Readings
1

Related records

Other records from Maves

All Maves programs and terms

Compounded semaglutide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 372 records of the same molecule.

Cite this entry

Treatment Registry. (2026). Maves — compounded semaglutide (TR-0262). Last verified September 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0262

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.